Literature DB >> 19968691

Detecting adverse events in dermatologic surgery.

Daniel Pinney1, Daniel J Pearce, Steven R Feldman.   

Abstract

BACKGROUND: Despite increasing awareness of and public attention to patient safety, little is documented about how adverse events (AEs) can or should be monitored in dermatologic surgery. Data to address this shortcoming are needed, although well-defined methodologies have yet to be implemented. OBJECTIVE To summarize current strategies in detecting adverse outcomes of dermatologic surgical procedures.
MATERIALS AND METHODS: A Medline literature search was conducted using the terms "adverse event,""detection,""reporting,""monitoring," and "surgery." Articles selected addressed the efficacy of one or more AE reporting techniques in surgical patients.
RESULTS: Prospective and retrospective reporting methods were identified, with morbidity and mortality conference being the most commonly used method of AE reporting. Retrospective medical record review, the retrospective trigger tool approach, and an anonymous electronic reporting system were more sensitive approaches. The Surgical Quality Improvement Program, a program that has successfully translated AE data into lower postoperative morbidity and mortality, was analyzed.
CONCLUSIONS: Although generally considered safe, dermatologic surgery has no current standard for AE reporting. Standard definitions and high-quality data regarding AEs" currently limit this analysis. Pilot studies are needed to develop feasible measures, with the goal of increasing the sensitivity of AE detection and ultimately improving patient outcomes.

Entities:  

Mesh:

Year:  2009        PMID: 19968691     DOI: 10.1111/j.1524-4725.2009.01378.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  1 in total

1.  Improvement in the detection of adverse drug events by the use of electronic health and prescription records: an evaluation of two trigger tools.

Authors:  Ugochi Nwulu; Krishnarajah Nirantharakumar; Rachel Odesanya; Sarah E McDowell; Jamie J Coleman
Journal:  Eur J Clin Pharmacol       Date:  2012-06-17       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.